

**PATIENT INFORMATION**
 Deliver Here

 Patient Name: \_\_\_\_\_  
 DOB: \_\_\_\_\_ Gender:  Male  Female  
 Address: \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip: \_\_\_\_\_  
 Primary Phone: \_\_\_\_\_ SSN: \_\_\_\_\_  
 Caregiver Name: \_\_\_\_\_  
 Alternate Phone: \_\_\_\_\_

**PRESCRIBER INFORMATION**
 Deliver Here

 Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_  
 NPI #: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_ Phone: \_\_\_\_\_

Please fax a copy of front and back of the insurance card(s).

**Clinical Information**

 Diagnosis:  L20. \_\_\_\_ (Atopic Dermatitis)     L40.0 (Psoriasis vulgaris/Plaque Psoriasis/Nummular Psoriasis)     L40.8 (Other psoriasis)  
                    L40.9 (Psoriasis, unspecified)     L40.5 \_\_\_\_ (Psoriatic arthritis)     L73.2 (Hidradenitis Suppurativa)  
 Other (ICD 10 code and description): \_\_\_\_\_    Wt: \_\_\_\_\_  Kg  lbs    Ht: \_\_\_\_\_  cm  in  
 Diagnosis Date: \_\_\_\_\_ TB/PPD test:  Positive  Negative    HBV:  Yes  No    If yes, currently treated:  Yes  No  
 Prior Therapy:  Yes  No \_\_\_\_\_  
 Reason for Discontinuation of therapy: \_\_\_\_\_  
 Start Date: \_\_/\_\_/\_\_\_\_    End Date: \_\_/\_\_/\_\_\_\_  
 Allergies:  NKDA  Other: \_\_\_\_\_  
 Comorbidities: \_\_\_\_\_  
 Concomitant Medications: \_\_\_\_\_

Drug	Dose/Strength	Directions	Qty	Refills
<input type="checkbox"/> <b>CIMZIA</b> (certolizumab)	<input type="checkbox"/> 200 mg/mL Prefilled Syringe <input type="checkbox"/> 200mg Vial	<input type="checkbox"/> Loading Dose: Inject 400mg SC at week 0, week 2 and week 4 <input type="checkbox"/> Maintenance Dose: Inject 200mg SC every 2 weeks <input type="checkbox"/> Maintenance Dose: Inject 400mg SC every 4 weeks		
<input type="checkbox"/> <b>COSENTYX</b> (secukinumab)	<input type="checkbox"/> 150mg/mL Sensoready Pen <input type="checkbox"/> 150mg/mL prefilled syringe <input type="checkbox"/> 150mg vial	<b>Plaque Psoriasis</b> <input type="checkbox"/> Loading dose: Inject 300mg SC at Weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Maintenance dose: Inject 300mg SC every 4 weeks <b>Psoriatic Arthritis</b> <input type="checkbox"/> Loading Dose: Inject 150mg SC at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Maintenance Dose: Inject 150mg Sc every 4 weeks <input type="checkbox"/> Other: _____		
<input type="checkbox"/> <b>DUPIXENT</b> (dupilumab)	<input type="checkbox"/> 300 mg/2 mL prefilled syringe <input type="checkbox"/> 200 mg/1.14 mL prefilled syringe	<b>Patients weighing ≥60kg</b> <input type="checkbox"/> Loading dose: Inject 600mg SC at week 0 <input type="checkbox"/> Maintenance dose: Inject 300mg SC every other week <b>Patients weighing &lt;60kg</b> <input type="checkbox"/> Loading dose: Inject 400mg SC on Day 1 <input type="checkbox"/> Maintenance dose: Inject 200mg SC every other week		
<input type="checkbox"/> <b>ENBREL</b> (etanercept)	<input type="checkbox"/> 50 mg/mL prefilled syringe <input type="checkbox"/> 50 mg/mL SureClick Autoinjector <input type="checkbox"/> 50 mg/mL cartridge	<input type="checkbox"/> Inject 50mg SC once weekly <input type="checkbox"/> Inject 50mg SC twice weekly <input type="checkbox"/> Inject ____mg (0.8mg/kg) SC once weekly		

 Injection training provided by:  Prescriber's office  Pharmacy  Other: \_\_\_\_\_

 Product substitution permitted     Dispense as written

Prescriber's Signature: \_\_\_\_\_ Date: \_\_\_\_\_